Remarkably, one subject was reported to have a transient complete response to IL-13Rα2-directed CAR T cell treatment, though disease recurrence 228 days after initial CAR T treatment with diminished IL-13Rα2 expression in the tumor was reported [56,100]. Here, IL13RA2 is linked to neoplasm.